NCT02672228

Brief Summary

This is a proof of concept study that will evaluate the feasibility of a vapor nanobubble technology (MalariSense) for malaria diagnostics. The MalariSense technology will use a highly innovative approach based on the transdermal non-invasive detection of vapor nanobubbles produced by the excitation of malaria-specific hemozoin by safe, low-energy laser pulse. The objectives of this study will be to determine the sensitivity and specificity of MalariSense in diagnosing malaria in malaria suspected cases attending a health facility in The Gambia and to identify factors influencing the diagnostic accuracy of MalariSense

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
208

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2015

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 14, 2015

Completed
17 days until next milestone

Study Start

First participant enrolled

October 1, 2015

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
2 months until next milestone

First Posted

Study publicly available on registry

February 3, 2016

Completed
Last Updated

March 22, 2018

Status Verified

March 1, 2018

Enrollment Period

2 months

First QC Date

September 14, 2015

Last Update Submit

March 20, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • "Hemozoin-generated vapour nanobubble (H-VNB) amplitude thresholds among malaria infected and uninfected individuals"

    Day 1

Secondary Outcomes (2)

  • Safety profile of Malarisense technology for malaria diagnosis

    Day 1 - Day 3

  • Correlation of incidence rate ratio of hemozoin-positive traces with level of parasite density as determined by microscopy

    Day1 - Day 3

Study Arms (1)

MalariaSense device

EXPERIMENTAL

This study will involve the evaluation of a medical diagnostic device. All participants enrolled in the study will be assessed for malaria using MalariSense Technology and will aslo get rapid diagnostic tests (RDTs), microscopy, PCR

Device: MalariaSense device

Interventions

All participants enrolled in the study will be assessed for malaria using the intervention device called MalariaSense technology

MalariaSense device

Eligibility Criteria

Age1 Year+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients presenting to the health facility with suspected uncomplicated malaria
  • Provision of informed consent

You may not qualify if:

  • Neonates and under 12 months old
  • Pregnant women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Basse Health Centre

Basse, Upper River Region, The Gambia

Location

MeSH Terms

Conditions

Malaria

Condition Hierarchy (Ancestors)

Protozoan InfectionsParasitic DiseasesInfectionsMosquito-Borne DiseasesVector Borne Diseases

Study Officials

  • Umberto D'alessandro, PhD, MD

    Medical Research Council Unit, The Gambia

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 14, 2015

First Posted

February 3, 2016

Study Start

October 1, 2015

Primary Completion

December 1, 2015

Study Completion

December 1, 2015

Last Updated

March 22, 2018

Record last verified: 2018-03

Locations